IDORSIA LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.208 CHF | -2.13% |
|
-5.88% | +4.45% |
| May. 21 | Idorsia Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| May. 21 | Swiss Stocks Flash Red Amid Economic Data Focus in Europe | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Calendar
2024-06-13
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
2.208
CHF
Average target price
1.692
CHF
Spread / Average Target
-23.35%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.45% | 442M | |
| +10.79% | 115B | |
| +11.65% | 106B | |
| -6.20% | 24.69B | |
| -2.33% | 21.97B | |
| -6.03% | 19.27B | |
| -13.41% | 17.56B | |
| -40.50% | 17.32B | |
| +6.64% | 14.03B | |
| +31.84% | 12.13B |
- Stock Market
- Equities
- IDIA Stock
- News Idorsia Ltd
- Idorsia Boosts Consent Fee Offer to 2024 Convertible Bond
